All In Biotech

Drug Trial Radar · NCT05222633

Anti-VEGF in Real-world

Observation of Anti-vascular Endothelial Growth Factor Therapy in Exudative Age-related Macular Degeneration, Proliferative Diabetic Retinopathy, Macular Edema, and Choroidal Neovascularization.

Last checked: Nov 20, 2026Latest source record: Feb 3, 2022 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknown

Status

Status unknown

Enrollment

1,000

Planned (sponsor's estimate)

Start

Jan 1, 2022

Primary completion

Jan 1, 2023

Study completion May 1, 2023

Sponsor

Lead sponsor
Wenbin WeiAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Feb 3, 2022

More drug trials from this sponsor

Design

Study type
Observational
FDA-regulated drug
No
Who can join
All sexes, from 35 years, up to 80 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

Anti-vascular endothelial growth factor therapy is the major intervention for treating ischemic retina diseases. According to FDA and China Food and Drug Administration, Ranibizumab, Aflibercept, and Conbercept are major types of anti-vascular endothelial growth factor therapy drugs. In the current study, the primary aim is to observe the visual acuity, anatomy effect of anti-vascular endothelial growth factor therapy in the real-world setting.

Conditions

  • Neovascular Age-related Macular Edema
  • Diabetic Macular Edema
  • Choroidal Neovascular Membrane
  • Non-proliferative Diabetic Retinopathy
  • Retinal Vein Occlusion
  • Proliferative Diabetic Retinopathy

Interventions

  • RanibizumabDrug

    Ranibizumab 0.5mg/0.05ml intravitreal injection

  • AfliberceptDrug

    Aflibercept 2.0mg/0.05ml intravitreal injection

  • ConberceptDrug

    Conbercept 0.5mg/0.05ml intravitreal injection

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Visual acuityTime frame: 1 year
  2. Central subfield thicknessTime frame: 1 year

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Wen-Bin Wei

    Beijing, Beijing Municipality, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.